The deal has a value of up to $330 million, with the final price tied to future sales of Optinose's flagship product.

Emcure Pharmaceuticals shares surged 10% to ₹1,288.65, driven by strong Q4FY25 results with a 64% profit increase. The ...

Vertex Pharmaceuticals has solid revenue projections for its CF franchise, and a promising drug pipeline, especially in pain.

The world of franchising is diverse in terms of industries as well as participants. Kalindi Thakrar found a path to build on ...

Emcure Pharma achieves robust Q4FY25 performance with 19% revenue growth and 63% profit after tax growth: Our Bureau, Mumbai Friday, May 23, 2025, 13:45 Hrs [IST] Emcure Pharma ha ...

Sun Pharmaceutical Industries Ltd. posted a mixed fourth quarter on Thursday and announced a softer-than-expected financial ...

Pune-headquartered pharma company Emcure Pharmaceuticals on Thursday reported that its Profit After Tax or net profit in the January-March 2025 quarter grew 63 per cent to Rs 197 crore. In the same ...

Emcure’s domestic business grew by 24.8% YoY in Q4FY25 led by its women’s health and cardio franchises and dermatology ...

Emcure Pharmaceuticals today announced strong performance across both its domestic and international businesses.

The Danish drugmaker unveiled a series of initiatives to increase access to Wegovy and clamp down on use of the knock-off ...

Emcure Pharmaceuticals on Thursday reported a 63 per cent rise in consolidated profit after tax (PAT) to Rs 197 crore during ...

Emcure Pharmaceuticals reported a 63% surge in net profit for Q1 2025, reaching Rs 197 crore, compared to Rs 121 crore in the ...